You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 7,135,305


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,135,305
Title:Methods for controlling the lysis of coagulated blood with apolipoprotein e4 phenotype
Abstract: Methods for inhibiting lysis of coagulated blood and reducing risk of excessive lysis comprising administration of lysis-inhibiting amounts of apolipoprotein E4, and methods for inhibiting lysis of coagulated blood and reducing risk of excessive lysis comprising administration of a specific level of a lysis-inhibiting agent wherein the specific level is based on the apolipoprotein phenotype of an individual, are provided. Methods for enhancing lysis of coagulated blood by administration of an Apo E peptide fragment to blood containing a clot lysis agent are also provided.
Inventor(s): Broderick; Joseph P. (Cincinnati, OH), Clark; Joseph F. (Cincinnati, OH), Woo; Daniel (Cincinnati, OH)
Assignee:
Application Number:10/398,882
Patent Claims:1. A method for inhibiting lysis of coagulated blood, comprising administering to blood a lysis-inhibiting amount of apolipoprotein E4 (Apo E4) or a therapeutic derivative thereof.

2. The method as defined by claim 1, wherein the blood comprises a clot lysis agent.

3. The method as defined by claim 2, wherein the clot lysis agent comprises tissue plasminogen activator (t-PA).

4. The method as defined by claim 2, wherein the clot lysis agent comprises a t-PA derivative.

5. The method as defined by claim 2, wherein the clot lysis agent comprises TNK-t-PA, t-PA, reteplase, streptokinase, heparin, coumadin, GIIb IIIa receptor blockers, therapeutic derivatives thereof, or mixtures thereof.

6. The method as defined by claim 1, wherein a therapeutic derivative comprising fragments of Apo E4 having lysis-inhibiting activity is administered.

7. The method as defined by claim 1, wherein the lysis-inhibiting amount of Apo E4 is administered to an individual with an ischemic disease.

8. The method as defined by claim 7, wherein the ischemic disease comprises myocardial infarction, unstable angina, coronary artery thrombus, or peripheral vascular disease.

9. The method as defined by claim 8, wherein the peripheral vascular disease comprises occlusion, retinopathy, or organ embolism.

10. The method as defined by claim 9, wherein the organ embolism comprises pulmonary embolism.

11. The method as defined by claim 1, wherein the lysis-inhibiting amount of Apo E4 is administered to an individual with post surgical complications of occlusion or clotting.

12. A method for reducing risk of excessive blood clot lysis, comprising administering to blood a lysis-inhibiting amount of Apo E4 or a therapeutic derivative thereof.

13. A method for inhibiting lysis of coagulated blood, comprising administering to an individual's blood a specific level of a lysis-inhibiting amount of Apo E4, wherein the specific level is based upon an apolipoprotein phenotype of the individual.

14. The method as defined by claim 13, wherein the apolipoprotein phenotype is Apo E4.

15. The method as defined by claim 13, wherein the blood comprises a clot lysis agent.

16. The method as defined by claim 15, wherein the clot lysis agent comprises tissue plasminogen activator (t-PA).

17. The method as defined by claim 15, wherein the clot lysis agent comprises a t-PA derivative.

18. The method as defined by claim 15, wherein the clot lysis agent comprises TNK-t-PA, t-PA, reteplase, streptokinase, heparin, coumadin, GIIb IIIa receptor blockers, therapeutic derivatives thereof, or mixtures thereof.

19. The method as defined by claim 13, wherein a therapeutic derivative comprising fragments of Apo E4 having lysis-inhibiting activity is administered.

20. The method as defined by claim 13, wherein the individual has an ischemic disease.

21. The method as defined by claim 20, wherein the ischemic disease comprises myocardial infarction, unstable angina, coronary artery thrombus, or peripheral vascular disease.

22. The method as defined by claim 21, wherein the peripheral vascular disease comprises occlusion, retinopathy, or organ embolism.

23. The method as defined by claim 22, wherein the organ embolism comprises pulmonary embolism.

24. The method as defined by claim 13, wherein the lysis-inhibiting amount is administered to an individual with post surgical complications of occlusion or clotting.

25. The method as defined by claim 13, comprising the additional step of determining the individual's apolipoprotein phenotype prior to administering the specific level of lysis-inhibiting Apo E4.

26. A method for reducing risk of excessive blood clot lysis, comprising administering to an individual's blood a specific level of a lysis-inhibiting amount of Apo E4, wherein the specific level is based upon an apolipoprotein phenotype of the individual.

27. The method as defined by claim 26, comprising the additional step of determining the individual's apolipoprotein phenotype prior to administering the specific level of lysis-inhibiting Apo E4.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.